| mln. INR | 2011 | 2012 | 2013 | 2014 | 2015 | 2015/2014 |
|---|---|---|---|---|---|---|
| P&L | ||||||
| Revenue | 1,142 | 1,620 | 1,204 | 931 | 1,571 | 68.7% |
| EBITDA | 102 | 137 | 199 | |||
| Net Income | -140 | -83 | -7 | 26 | -49 | -289.6% |
| Balance Sheet | ||||||
| Cash | 51 | 48 | ||||
| Short Term Debt | 0 | 588 | ||||
| Long Term Debt | 1,334 | 672 | ||||
| Cash flow | ||||||
| Ratios | ||||||
| Revenue growth | -37.5% | 41.9% | -25.7% | -22.6% | 68.7% | |
| EBITDA growth | -60.3% | 34.7% | 45.2% | |||
| EBITDA Margin | 8.9% | 8.5% | 16.5% | 0.0% | 0.0% | 0.0% |
| Net Income Margin | -12.3% | -5.1% | -0.6% | 2.8% | -3.2% | -6.0% |
| ROIC | 2.0% | 0.0% | ||||
| ROE | -14.9% | 0.0% | ||||
| Net Debt/EBITDA | 12.6x | 0.0x | 6.1x | 0.0x | ||
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|
| Mangalam Drugs & Organics ($MANGALAM) | 16.6% | -18.2% | -2.1% | 79.8% | |
| Sun Pharmaceutical Industries ($SUNPHARMA) | 39.9% | 40.4% | 42.4% | 70.2% | |
| Marksans Pharma ($MARKSANS) | 16.7% | 23.3% | 43.3% | 26.8% | |
| Torrent Cables ($TORRCABS) | 27.5% | 17.4% | -42.9% | 26.5% | |
| Lincoln Pharmaceuticals ($LINCOPH) | 6.3% | 3.8% | 8.5% | 25.9% | |
| Median (41 companies) | 16.6% | 14.9% | 13.7% | 8.6% | |
| Lyka Labs ($LYKALABS) | 41.9% | -25.7% | -22.6% | 68.7% | |
| Top | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|
| Dr.Reddy'S Laboratories ($DRREDDY) | 52.1% | 57.4% | 57.6% | ||
| Omega Laboratories ($OMEGALAB) | 0.0% | 0.0% | 0.0% | 0.0% | |
| Median (2 companies) | 46.9% | 26.1% | 28.7% | 28.8% | |
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|
| Divi'S Laboratories ($DIVISLAB) | 38.1% | 37.2% | 38.2% | 40.2% | 37.4% |
| Hester Biosciences ($HESTERBIO) | 32.9% | ||||
| Sun Pharmaceutical Industries ($SUNPHARMA) | 34.3% | 40.8% | 44.3% | 44.9% | 29.2% |
| Natco Pharma ($NATCOPHARM) | 21.3% | 21.5% | 23.2% | 24.9% | 26.2% |
| Dr.Reddy'S Laboratories ($DRREDDY) | 21.7% | 25.8% | 22.9% | 25.1% | 23.2% |
| Median (54 companies) | 16.5% | 12.9% | 12.8% | 14.5% | 12.1% |
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|
| Claris Lifesciences ($CLARIS) | 32.5% | 58.1% | 42.9% | 103.1% | |
| Wintac ($WINTAC) | 22.8% | ||||
| Hester Biosciences ($HESTERBIO) | 21.5% | ||||
| Ipca Laboratories ($IPCALAB) | 10.3% | 11.2% | 8.3% | 11.6% | 17.8% |
| Natco Pharma ($NATCOPHARM) | 20.0% | 24.4% | 16.3% | 14.4% | 14.1% |
| Median (32 companies) | 7.4% | 8.0% | 7.9% | 5.8% | 6.1% |
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|
| Marksans Pharma ($MARKSANS) | -25.8% | -142.4% | 34.9% | 33.8% | 41.2% |
| Alembic Pharmaceuticals ($APLLTD) | 27.5% | 29.1% | 41.5% | 35.7% | |
| Jenburkt Pharmaceuticals ($JENBURPH) | 43.6% | 34.1% | 29.0% | 32.4% | 35.3% |
| Abbott India ($ABBOTINDIA) | 36.0% | 29.6% | 26.9% | 30.5% | 34.2% |
| Divi'S Laboratories ($DIVISLAB) | 25.6% | 30.6% | 30.4% | 32.3% | 30.5% |
| Median (63 companies) | 14.0% | 13.9% | 13.4% | 15.0% | 13.2% |
| Lyka Labs ($LYKALABS) | 2.0% | ||||
| Top 5 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|
| Jubilant Life Sciences Limited ($JUBILANT) | 5.3x | 4.0x | 3.5x | 3.5x | 6.4x |
| Shasun Pharmaceuticals ($SHASUNPHAR) | 4.5x | 2.8x | 4.5x | 6.0x | 6.2x |
| Claris Lifesciences ($CLARIS) | 1.5x | 1.9x | 1.1x | 1.8x | 3.2x |
| Dishman Pharmaceuticals & Chemicals ($DISHMAN) | 3.7x | 3.6x | 2.6x | 2.3x | 2.9x |
| Neuland Laboratories ($NEULANDLAB) | 4.9x | 4.2x | 3.5x | 2.6x | 2.6x |
| Median (49 companies) | 1.5x | 1.6x | 1.2x | 0.4x | 0.1x |
